HK Stock MarketDetailed Quotes

01643 MODERN CHI MED

Watchlist
  • 0.320
  • 0.0000.00%
Market Closed Apr 19 16:08 CST
192.00MMarket Cap3.56P/E (TTM)

About MODERN CHI MED Company

Hyundai Traditional Chinese Medicine Group Co., Ltd. is one of the pioneers in the modernization of traditional Chinese medicine in China. Our main subsidiary, Chengde Omuro Jindan Pharmaceutical Co., Ltd., is a proprietary Chinese medicine pharmaceutical company with a long history. Our development history can be traced back to 1986. Adhering to the corporate mission of “building the national traditional Chinese medicine industry and focusing on the healthy development of national traditional Chinese medicine”, we have always focused on the innovative development of qi and blood supplements, cardiovascular and cerebrovascular drugs, digestive system, proprietary gynaecological medicines, COVID-19, and/or similar conditions (starting in FY2020). We have 71 drug approval numbers and produce 59 types of proprietary Chinese medicine products. Of these, 45 products are included in the “National Medical Insurance Drug Catalogue”. It is a leading manufacturer of proprietary Chinese medicine pills and cardiovascular and cerebrovascular proprietary Chinese medicine capsules in Northeast China. We have major product groups such as Qi and Blood Double Supplement Pills, Kidney Supplement Pills, Shanmei Capsules, Jinqui Kidney Qi Pills, Xinan Capsules, Flavoured Xiaoyao Pills, Flavoured Agastache Zhengqi Pills, Qingfeng Detox Pills, and Liver Protectors. Among them, the three major products of kidney filling pills, qi and blood double supplement pills, and Shanmei capsules occupy leading positions in the market. We have implemented a strict quality control system, established a sound enterprise management system and various operating rules, built a first-class management, production and distribution elite team, and achieved standardized enterprise management. We promote enterprise development through research and development, and have signed cooperation agreements with Heilongjiang University of Traditional Chinese Medicine and Chengde Medical College to jointly develop new drugs and strengthen our product expertise. The company's main product, Shanmei capsule, is an original research drug. It was issued a new drug certificate by the Ministry of Health of China in 1995. It was listed as a second-level protected traditional Chinese medicine by the China Drug Administration. In 2016, it was awarded the title of a famous brand product for small and medium-sized enterprises in Hebei Province by the Hebei Provincial Department of Industry and Information Technology. Based on our geography and our own advantages, we are based in Hebei and are deeply involved in the North China and Northeast China markets while vigorously expanding the East China, South China, Southwest and Northwest China markets, gradually building an efficient marketing network covering the whole country. After years of development, we have established a unique brand advantage. “Omuro” brand products are trusted by many customers due to their competitiveness and diverse combinations, and have always enjoyed a good reputation in the national pharmaceutical market. Entering the 21st century, the company formulated a “grouping, intensification and internationalization” development direction, with the aim of striving to build a domestic first-class, internationally renowned large-scale traditional Chinese medicine pharmaceutical group.

Company Profile

Symbol01643
Company NameMODERN CHI MED
ISINKYG6181B1068
Listing DateJan 15, 2021
Issue Price1.18
Shares Offered150.00M share(s)
FoundedAug 12, 2019
Registered AddressCayman Islands
Chairmanxinlei sun
Secretaryzixijiayanru chen
Audit InstitutionChina Audit Zhonghuan (Hong Kong) Certified Public Accountants Limited
Company CategoryOverseas registration of Mainland Individuals control
Registered Office89 Nexus Way, Camana Bay Grand Cayman Cayman Islands KY1-9009
Head Office and Principal Place of BusinessRoom 2404, Universal Tower, 19 Des Voeux Road Central, Hong Kong
Fiscal Year Ends12-31
Employees191
MarketHong Kong motherboard
Phone(852)29801967
Fax(852)29801967
EmailIR@cdysjdyy.com
Business Hyundai Traditional Chinese Medicine Group Co., Ltd. is a Chinese investment holding company that mainly produces proprietary Chinese medicines. The company mainly provides over-the-counter and prescription drugs for middle-aged and elderly people. The company's main products are kidney supplement pills, qi and blood double supplement pills, Shanmei capsules, Jin Qu kidney gas pills, Xinan capsules, flavored Xiaoyao pills, liver protection tablets, flavored agastache tablets, and Qingfeng detoxification pills. The company is also engaged in the production of other traditional Chinese medicines designed to treat or relieve other symptoms of discomfort such as psychological, respiratory and pediatric. The company mainly operates in the domestic market.

Company Executives

  • Name
  • Position
  • Salary
  • hongli zhang
  • CEO,Executive Director,Remuneration Committee Members,Authorized Representative
  • --
  • xinlei sun
  • Chairman of the Board,Executive Director
  • --
  • jinglian li
  • Chief Operating Officer
  • --
  • zhendong jiang
  • Deputy General Manager
  • --
  • ling liu
  • Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Members,Nomination Committee Members
  • --
  • zirong liang
  • Independent Non-Executive Director,Chairman of the Audit Committee
  • --
  • zhijian huang
  • Independent Non-Executive Director,Chairman of the Nomination Committee,Audit Committee Members,Remuneration Committee Members
  • --
  • wentao li
  • chief financial officer
  • --
  • yanru jia
  • Director of the Board of Directors Office,Executive Director,Joint Company Secretary,Nomination Committee Members
  • --
  • zixi chen
  • Joint Company Secretary,Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg